Latest Stock Research & Market Analysis
Search All Research, Articles & Stock Profiles
ASX Stock Research
[BUY] BlueScope Steel (ASX: BSL) – Capex Peaks and Cash Flow Inflects
BlueScope Steel (ASX: BSL) at A$32.00, on 6x forward EBITDA against steel peers near 7x. Capex has peaked and free cash flow inflects. Buy, about 18% upside.
[BUY] Aristocrat Leisure (ASX: ALL) – A Billion-Dollar Interactive Path
Aristocrat Leisure (ASX: ALL) at A$61.40, charting a path to US$1bn in Interactive revenue by FY29 as iGaming and iLotteries scale. Buy, around 14% upside.
[BUY] Worley (ASX: WOR) – Selloff Overshoots the Earnings Trim
Worley (ASX: WOR) at A$10.94, around 10x forward EV/EBIT after an overdone selloff. The earnings trim is modest, the growth case intact. Buy, about 35% upside.
[BUY] ResMed (ASX: RMD) – Growth Levers in Place for a Re-Rate
Buy ResMed at A$26.68 with a A$46.70 target and 75% upside. The GLP-1 fear is fading, new growth levers are scaling, and it trades below medtech peers.
[BUY] Collins Foods (ASX: CKF) – Qld and WA Exposure Outweighs the Wage Cost Squeeze
Collins Foods (ASX: CKF) at A$8.27 trades ~20% below its historical PE. Qld/WA exposure plus a kiosk rollout offset wage pressure. 29% upside, Buy.
Global Marco and Market Research
The $9k Hit to Property Investors. Why Most Won’t Reallocate.
The FY2027 housing tax overhaul costs a typical new property investor ~$9k a year in cash flow and 1.9ppt in 10-yr returns. Why most won’t sell.
Corporate Profits Are at Record Highs. AI Could Make the Gap Even Wider.
US corporate profits have roughly doubled as a share of GDP since the 1980s while the top 1 per cent of firms now control 80 per cent of sales. New economics research spanning a century of data finds concentration accounts for a third of the margin increase, and history suggests AI will widen the gap further.
Australia’s Biggest CGT Change in 25 Years. What It Means for Investors.
The FY2027 Commonwealth Budget delivered the biggest change to capital gains tax since 1999. Institutional sell-side economics research assessed the Budget as broadly deficit-neutral at the headline level but incrementally expansionary for GDP growth once off-balance...
Global Stock Research
[BUY] Interactive Brokers (NASDAQ: IBKR) – Record DARTs and Account Growth Reset the Earnings Power
Interactive Brokers closed at US$86.97 on 29 May ahead of its monthly metrics release for May 2026, and the print that followed has reset the upside in our view. Institutional sell-side research has IBKR rated Buy with a 12-month price target lifted to US$109,...
[BUY] Walmart (NYSE: WMT) – Share Gains and Digital Flywheel Drive the Next Leg
Walmart closed down 7.3% after its 1Q26 earnings beat and management reiterated full-year guidance, creating what we think is an attractive entry point for the world's largest retailer. Institutional sell-side research has Walmart rated Buy with a 12-month price...
[BUY] MongoDB (MDB): The AI Data Layer Play With a Clear Path to $4bn Revenue
MongoDB (MDB) is rated a Buy with a US$360 price target, implying 8 per cent upside. The thesis rests on Atlas cloud consumption growth, an AI-native product strategy, and an earnings trajectory that compresses the P/E from 55x to 36x by FY29.
[BUY] Upwork (NASDAQ: UPWK) – Restructuring Sharpens the Margin Story
Upwork delivered a Q1'26 result that landed on the right side of a bifurcated narrative. Revenues came in around the midpoint of guidance at $195mn, while Adj. EBITDA of $57mn...
[BUY] Eli Lilly (LLY): Foundayo Reframes the Oral GLP-1 Story
LLY Buy with ~37% upside to ~US$1,283. 1Q26 EPS US$8.55 beat US$6.77, 2026 guide raised to US$82-85bn. Foundayo oral GLP-1 hits 8k prescribers in 3 weeks, 80% new incretin patients.
Region & Industry Outlook
Why China Is Pricing a Stability Premium
China has spent three years priced for an accident. In 2026 the macro picture has flipped, with growth holding above 4.5%, inflation reflating off the floor, USD/CNY rolling lower, and the equity wrappers leading the rerating off the 2024 lows.
Why Gold Miners Still Have Room to Run
Gold has had a turbulent few months. Spot gold ran from around US$3,400/toz at the end of 2025 to a peak above US$5,300/toz in early 2026 on a wave of speculative call-option demand and continued central bank diversification. The Iran shock in late March then...
Semis Are Still Riding the AI Capex Wave
The semiconductor cycle is in a constructive setup, with the AI capital expenditure build-out continuing to pull through capacity commitments, design wins, and sub-segment by sub-segment recoveries. March monthly shipment data from the Semiconductor Industry...
ASX Announcement
Regis Resources (ASX: RRL) – Genesis Vault 1 Proposal Update
Regis Resources has decided not to exercise its matching right under the scheme implementation deed with Vault Minerals, clearing the final major hurdle for Genesis Minerals to acquire Vault. The decision, announced on 13 July 2026, removes the last contractual...
Regis Resources (ASX: RRL) – Regis Provides VAU Transaction Update
Vault Minerals Limited has signalled its intention to terminate its scheme of arrangement with Regis Resources Limited and proceed with a superior takeover proposal from Genesis Minerals Limited, ending an acquisition process that has taken a dramatic turn in recent...
oOh!media (ASX: OML) – oOh!media Updates Change of Control Proposals
Three private equity firms have reconfirmed their takeover proposals for oOh!media, with offers ranging from $1.60 to $1.65 per share. Pacific Equity Partners, I Squared Capital, and Oaktree Capital Management each lodged non-binding indicative offers (NBIOs) and have...
Clinuvel Pharmaceuticals (ASX: CUV) – SCENESSE Approved for EPP in Canada
Clinuvel Pharmaceuticals has achieved a significant regulatory milestone with Health Canada's approval of SCENESSE (afamelanotide) for the prevention of phototoxicity in adult...
City Chic Collective (ASX: CCX) – City Chic FY26 Third Trading Update
City Chic Collective has delivered a materially stronger earnings result for FY26, with underlying EBITDA forecast to reach $11.5 million to $12.5 million, representing an 80 to...
Top Stock Reports
5 Best Shares to Buy Right Now in Australia
Finding the best shares to buy on the ASX requires more than just scanning a screener or chasing whatever is up this week. We focus on companies with strong competitive positioning, visible earnings growth, and a catalyst to drive the share price higher over the next...
5 Best US Shares to Buy Right Now
US equities offer Australian investors access to some of the most innovative and fastest-growing companies in the world. The sheer depth of the American market means there are opportunities across sectors that simply do not exist on the ASX, from cutting-edge biotech...
5 Best Dividend Stocks to Buy [ASX Blue Chip Stocks]
Dividend investing on the ASX remains one of the most reliable ways to build long-term wealth. Blue chip dividend stocks offer a combination of regular income and capital growth that is difficult to replicate through other strategies, particularly in an environment...
Subscribe
Want more Free Research?
Subscribe today for free and get an alert when we have new research and webinars.
MF & Co. Asset Management
MF & Co. Asset Management is a boutique investment firm offering Equity Capital Markets and derivative general advice & trade execution services.
We are specialists in advising and trading in Australian and US Equities, Index & Equity Options and Options on Futures.
Contact
Get In Touch
Australia
1300 889 603
International
+61 2 8378 7199
M-F: 8am-5pm
Suite 803, Level 8
70 Pitt St, Sydney, NSW 2000